İn, Erdal

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/7652
Name Variants
In, Erdal
Job Title
Email Address
Main Affiliation
09. Faculty of Medicine
Status
Current Staff
Website
ORCID ID
0000-0002-8807-5853
Scopus Author ID
21742842200
Turkish CoHE Profile ID
Google Scholar ID
jOSmIdkAAAAJ
WoS Researcher ID
CBX-3046-2022

Sustainable Development Goals

SDG data is not available
Documents

36

Citations

416

h-index

10

Go to Scopus profile
Documents

35

Citations

178

Go to WoS profile
Scholarly Output

3

Articles

3

Views / Downloads

0/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

3

Scopus Citation Count

3

WoS h-index

1

Scopus h-index

1

Patents

0

Projects

0

WoS Citations per Publication

1.00

Scopus Citations per Publication

1.00

Open Access Source

2

Supervised Theses

0

JournalCount
Eurasian Journal of Pulmonology1
Medicina-Lithuania1
Scientific Reports1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2024 - 20253
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Review
    Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: Clinical Manifestations and Pulmonary Involvement
    (Kare Publ, 2024) Parlak, E.Ş.; Şengül, A.; İn, E.
    Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are necrotizing autoimmune vasculitis resulting from immune-mediated damage to small and medium-sized vessels. Three primary clinicopathological syndromes are defined in AAV: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The disease may present as alveolar hemorrhage due to a systemic inflammatory response, purpuric rash due to vascular rupture, or segmental glomerular infarction due to vascular occlusion. The lungs are commonly affected organs in AAV, with lung involvement categorized into five main groups: pulmonary capillaritis characterized by granulomatous inflammation (lung nodules), tracheobronchial inflammation, diffuse alveolar hemorrhage (DAH), interstitial lung disease (ILD), and asthma. DAH and ILD are associated with a poor prognosis. The treatment goal is to achieve remission and prevent relapses. © 2024 Eurasian Journal of Pulmonology Published by Kare Media.
  • Thumbnail Image
    Article
    Citation - WoS: 3
    Citation - Scopus: 3
    Diagnostic Value of Galectin-3 in Exacerbations of Chronic Obstructive Pulmonary Disease
    (MDPI, 2024) Kırıcı Berber, Nurcan; Atlı, Siahmet; Altıntop Geçkil, Ayşegül; Erdem, Mehmet; Kıran, Tuğba Raika; Otlu, Önder; İn, Erdal
    Background and Objectives: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease characterized by acute exacerbations. Systemic inflammation and oxidative stress play an important role in the pathogenesis of COPD. Exacerbations in COPD reduce the quality of life and are associated with rapid disease progression. Galectin-3 is a beta-galactoside-binding lectin of approximately 30 kDa with pro-inflammatory and pro-fibrotic properties. This study aims to analyze the efficacy of serum galectin-3 in predicting exacerbations in COPD patients. Materials and Methods: Baseline demographic and clinical characteristics of all patients were recorded and blood samples were collected. A total of 58 consecutive COPD patients, including 28 patients (19 male and 9 female) with stable COPD and 30 patients (23 male and 7 female) with acute exacerbation of COPD (AECOPD), were included in the study. Results: Serum galectin-3 levels were significantly higher in the AECOPD group compared to the stable COPD group. A logistic regression analysis revealed that increased galectin-3 levels and disease duration were independent predictors of COPD exacerbation (OR = 5.322, 95% CI: 1.178-24.052, p = 0.03; and OR = 1.297, 95% CI: 1.028-1.635, p = 0.028; respectively). Conclusions: The results of our study demonstrated that Galectin-3 was a strong and independent predictor of exacerbations in COPD patients.
  • Thumbnail Image
    Article
    Oxygen Regulated Protein 150 Can Be Considered as a Severity Indicator in Obstructive Sleep Apnea
    (Nature Portfolio, 2025) Otlu, Onder; Erdem, Mehmet; Kiran, Tugba Raika; Inceoglu, Feyza; Geckil, Aysegul Altintop; Berber, Nurcan Kirici; In, Erdal
    Oxygen-regulated protein 150 (ORP150) is a chaperone found in the endoplasmic reticulum (ER) induced by ER stress, oxidative stress, glutamate toxicity, ischemia, and hypoxia. Increased expression of ORP150 protects the cells by stopping ER stress, maintaining calcium balance, and delaying apoptosis. In this study, we aim to investigate serum ORP150 amount in patients with different severity levels of obstructive sleep apnea (OSA). Forty-nine patients (25 of severe and 24 of mild-moderate), and 23 healthy controls were included in the study. Routine biochemical measurements and serum ORP150 measurements of all groups and sleep quality measurements of OSA groups were obtained. ELISA was used to measure ORP150 levels in serum samples. In addition, ROC analysis was performed to determine the diagnostic power of the ORP150 parameter. There are significant differences between all three groups in terms of ORP150 values (severe OSA: 8.03 +/- 0.4 ng/mL; mild-moderate OSA: 5.54 +/- 0.47 ng/mL; control: 4.41 +/- 0.25 ng/mL, p < 0.017). The highest ORP150 level belongs to the severe OSA group and there is a direct correlation between the severity of the disease and ORP150 levels. ORP150 value is a distinguishing parameter for OSA and the cut-off value of ORP150 was observed as 7.14 ng/mL. We concluded that serum ORP150 levels can be a differential diagnostic parameter in OSA patients and that disease severity can be determined by serum ORP150 measurement.